Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coral LaboratoriesBOM:524506 72 Interest Coverage is 560.43 as of Mar. 2026, which is 95% above its 10-year median of 287.26. GuruFocus rates BOM:524506 with a GF Score™ of 72/100 and a GF Value™ of ₹483.47 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 683 Drug Manufacturers companies, Coral Laboratories ranks better than 75.4% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Coral Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was ₹56.6 Mil. Coral Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was ₹-0.1 Mil.
Coral Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 560.43.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Coral Laboratories Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Coral Laboratories's Interest Coverage or its related term are showing as below:
BOM:524506'
s Interest Coverage Range Over the Past 10 Years
Min: 4.82 Med: 287.26 Max: 71318
Current: 76.27
BOM:524506's Interest Coverage is ranked better than 75.4% of 683
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs BOM:524506: 76.27
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Coral Laboratories Interest Coverage Related Terms
Coral Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Coral Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Coral Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coral Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Coral Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Coral Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coral Laboratories (BOM:524506) has a Interest Coverage of 560.43 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Coral Laboratories and its competitors. This is 95% above median its historical median of 287.26. Over the past decade, Coral Laboratories' Interest Coverage has ranged from 4.82 to 71,318.00. According to the industry distribution chart, Coral Laboratories ranks #168 out of 683 companies in the Drug Manufacturers industry, placing it in the top 24.6%.
Is Coral Laboratories' Interest Coverage too high?
Coral Laboratories' current Interest Coverage of 560.43 is 95% above median its 10-year median of 287.26. Over the past 10 years, this metric has ranged from a low of 4.82 to a high of 71,318.00. The Drug Manufacturers industry median Interest Coverage is 12.78. Coral Laboratories' value of 560.43 is 4285.2% above this industry median. Based on the distribution chart, Coral Laboratories ranks #168 out of 683 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Coral Laboratories has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coral Laboratories' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Coral Laboratories ranks #168 out of 683 companies for Interest Coverage. This places Coral Laboratories in the top 25% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.78. Coral Laboratories' value of 560.43 is 4285.2% above this benchmark. Historically, Coral Laboratories' own Interest Coverage has ranged from 4.82 to 71,318.00 over the past decade. While the company's 10-year median is 287.26 vs. the industry median of 12.78, Coral Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coral Laboratories's current Interest Coverage of 560.43 is 4285.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Coral Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coral Laboratories's current Interest Coverage is 560.43, which is 95% above median its own 10-year median of 287.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coral Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Coral Laboratories (BOM:524506) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹483.47, compared to a current price of ₹577.90 — trading 19.5% above its estimated fair value. The current Interest Coverage is 560.43, which is 95% above median its 10-year median of 287.26 and 4285.2% above the Drug Manufacturers industry median of 12.78. Coral Laboratories' overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Coral Laboratories (BOM:524506), the current Interest Coverage is 560.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coral Laboratories (BOM:524506) Overvalued in 2026?
Based on GuruFocus' analysis, Coral Laboratories stock appears to be overvalued.
The current stock price of ₹577.90 is trading 19.5% above its estimated GF Value™ of ₹483.47.
GuruFocus considers Coral Laboratories to be Modestly Overvalued.
Key valuation signals for BOM:524506:
Interest Coverage: 560.43 (95% above median its 10-year median of 287.26)
GF Value™: ₹483.47 vs. price of ₹577.90 (19.5% above fair value)
Industry Position: 4285.2% above the Drug Manufacturers median (#168 of 683)
No single metric tells the full story. See the BOM:524506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coral Laboratories Ltd is engaged in the pharmaceutical business. The company is involved in the formulation of medicines. The company's dosage form includes tablets, capsules, liquid orals, b-lactam, dry syrup, meter dose inhalers, injectables, drops, sprays, special kits, and others. Its geographical segments include Ethiopia, India, and the Rest of the world.
72GF Score
Get the complete analysis for BOM:524506
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524506 has been successfully added to your 
